Prognostic value of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. The Henry ord Hospal ardioulmonary Eercise Testing (FIT-CPX) project - 18/03/16
, Clinton A. Brawner, PhD b, Heather A. Aldred, PhD b, Barry Lewis, DO b, Celeste T. Williams, MD b, Christina Tita, MD b, John R. Schairer, DO b, Jonathan K. Ehrman, PhD b, Mauricio Velez, MD b, Yelena Selektor, MD b, David E. Lanfear, MD b, Steven J. Keteyian, PhD bRésumé |
Background |
Although cardiopulmonary exercise (CPX) testing in patients with heart failure and reduced ejection fraction is well established, there are limited data on the value of CPX variables in patients with HF and preserved ejection fraction (HFpEF). We sought to determine the prognostic value of select CPX measures in patients with HFpEF.
Methods |
This was a retrospective analysis of patients with HFpEF (ejection fraction ≥ 50%) who performed a CPX test between 1997 and 2010. Selected CPX variables included peak oxygen uptake (VO2), percent predicted maximum oxygen uptake (ppMVO2), minute ventilation to carbon dioxide production slope (VE/VCO2 slope) and exercise oscillatory ventilation (EOV). Separate Cox regression analyses were performed to assess the relationship between each CPX variable and a composite outcome of all-cause mortality or cardiac transplant.
Results |
We identified 173 HFpEF patients (45% women, 58% non-white, age 54 ± 14 years) with complete CPX data. During a median follow-up of 5.2 years, there were 42 deaths and 5 cardiac transplants. The 1-, 3-, and 5-year cumulative event-free survival was 96%, 90%, and 82%, respectively. Based on the Wald statistic from the Cox regression analyses adjusted for age, sex, and β-blockade therapy, ppMVO2 was the strongest predictor of the end point (Wald χ2 = 15.0, hazard ratio per 10%, P < .001), followed by peak VO2 (Wald χ2 = 11.8, P = .001). VE/VCO2 slope (Wald χ2= 0.4, P = .54) and EOV (Wald χ2 = 0.15, P = .70) had no significant association to the composite outcome.
Conclusion |
These data support the prognostic utility of peak VO2 and ppMVO2 in patients with HFpEF. Additional studies are needed to define optimal cut points to identify low- and high-risk patients.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: Dr Ali Shafiq received support from a National Heart, Lung, and Blood Institute training grant (T32HL110837). |
Vol 174
P. 167-172 - avril 2016 Retour au numéro
Article précédent
- Dual health care system use is associated with higher rates of hospitalization and hospital readmission among veterans with heart failure
- R. Neal Axon, Mulugeta Gebregziabher, Charles J. Everett, Paul Heidenreich, Kelly J. Hunt
- Prosthetic valve thrombosis: When prevention is better than treatment
- Vincenzo Tarzia, Alvise Guariento, Lorenzo Bagozzi, Andrea Bagno, Tomaso Bottio, Gino Gerosa
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?